DS6000-126 REJOICE-PanTumor01

• Research type

  Research Study

• Full title

  REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

• IRAS ID

  1011089

• Contact name

  Bettina Steffens

• Contact email

  TBEU-clinicaltrials@daiichi-sankyo.eu

• Sponsor organisation

  Daiichi Sankyo, Inc.

• Clinicaltrials.gov Identifier

  NCT06660654

• Research summary

  This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma [ccRCC]).

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  25/SC/0066

• Date of REC Opinion

  30 May 2025

• REC opinion

  Further Information Favourable Opinion